KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Debt to Equity (2016 - 2026)

Abbott Laboratories' Debt to Equity history spans 18 years, with the latest figure at $0.65 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 135.65% to $0.65 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.65, a 135.65% increase, with the full-year FY2025 number at $0.25, down 99.64% from a year prior.
  • Debt to Equity hit $0.65 in Q1 2026 for Abbott Laboratories, up from $0.25 in the prior quarter.
  • Over the last five years, Debt to Equity for ABT hit a ceiling of $358.02 in Q4 2023 and a floor of -$624.12 in Q3 2024.
  • Historically, Debt to Equity has averaged $5.69 across 5 years, with a median of $0.28 in 2025.
  • Biggest five-year swings in Debt to Equity: surged 52642.05% in 2023 and later plummeted 33984.11% in 2024.
  • Tracing ABT's Debt to Equity over 5 years: stood at $0.68 in 2022, then surged by 52642.05% to $358.02 in 2023, then tumbled by 81.21% to $67.26 in 2024, then plummeted by 99.64% to $0.25 in 2025, then surged by 166.93% to $0.65 in 2026.
  • Business Quant data shows Debt to Equity for ABT at $0.65 in Q1 2026, $0.25 in Q4 2025, and $0.25 in Q3 2025.